New drug duo aims to shrink tumors before surgery for Tough-to-Treat bladder cancer
NCT ID NCT05394337
Summary
This study is testing whether a combination of two immunotherapy drugs, atezolizumab and tiragolumab, can help control high-risk bladder cancer when given before surgery to remove the bladder. It is for patients who are not eligible for the usual pre-surgery chemotherapy. The main goals are to see if the treatment is safe and if it can shrink or eliminate the tumor before the operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.